Merck reported its sixth consecutive earnings beat with strong revenue growth driven by new drugs like Keytruda and raised its profit outlook for 2026. Despite this, the stock faces a significant patent cliff, especially with Keytruda facing generic competition in 2027, which could pressure sales. The company’s pipeline, including promising Phase 3 trial results for sac-TMT and other drugs, is seen as crucial to offsetting these risks and driving long-term growth toward a $70 billion revenue target in the mid-2030s. Analysts remain cautious with a hold rating, noting the stock’s current high valuation already prices in expected pipeline success.
As of Nov 04, 2026 01:21 WIB, Merck & Co., Inc. (MRK) trades at USD 144.88 on Pluang, down 2.35% for the day. The stock shows strong investor interest with 94% of orders to buy and a typical hold time of 97 days. Despite the recent earnings beat and pipeline optimism, the market cap stands at $366.03 billion, reflecting cautious sentiment amid high valuation and upcoming patent challenges.
Moderna's stock rose 5% ahead of its earnings report, continuing a strong 685% gain this year, driven by its mRNA vaccine focus and oncology pipeline. Pfizer's shares fell 0.8% despite beating Q3 revenue estimates and raising its 2026 guidance, as CO...
Regeneron Pharmaceuticals' stock surged 12% after reporting a 36% revenue increase to $5.1 billion in Q3 2026, beating analyst expectations. The boost was largely due to its partnership with Sanofi, with Dupixent sales rising 35%, and record sales of...
